Isoniazid inhibits human erythroid 5-aminolevulinate synthase: Molecular mechanism and tolerance study with four X-linked protoporphyria patients

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

卷:1863

Article

Fratz-Berilla, Erica J.¹  Breydo, Leonid^1,2  Gouya, Laurent^3,4,5  Puy, Herve^3,4,5  Uversky, Vladimir N.^1,2  Ferreira, Gloria C.^1,6 

[1] Univ S Florida, Dept Mol Med, Morsani Coll Med, MDC 7, Tampa, FL 33612 USA

[2] Univ S Florida, Morsani Coll Med, USF Hlth Byrd Alzheimers Res Inst, Tampa, FL USA

[3] Univ Paris Diderot, INSERM, U1149, Ctr Rech Inflammat, Site Bichat, Paris, France

[4] GR Ex, Lab Excellence, Paris, France

[5] Hop Louis Mourier, AP HP, Ctr Francais Porphyries, Colombes, France

[6] Univ S Florida, Dept Chem, Tampa, FL USA

关键词: 5-Aminolevulinate synthase;    Heme;    Porphyria;    Anemia;    Pyridoxal 5 '-phosphate;    Enzyme inhibitors;    Enzyme stuctures;   

DOI  :  10.1016/j.bbadis.2016.11.011

来源: Elsevier

【 摘 要 】

Mutations in the C-terminus of human erythroid 5-aminolevulinate synthase (hALAS2), a pyridoxal 5'-phosphate (PLP)-dependent enzyme, are associated with two different blood disorders, X-linked sideroblastic anemia (XLSA) and X-linked protoporphyria (XLPP). XLSA-causing mutations yield hALAS2 variants with decreased activity, while XLPP-causing mutations result in a gain-of-function of hALAS2. There are no specific treatments for XLPP. Isonicotinic acid hydrazide (isoniazid, INH), an antituberculosis agent, can cause sideroblastic anemia as a side-effect, by limiting PLP availability to hALAS2, via inhibition of pyridoxal kinase or reaction with pyridoxal to form pyridoxal isonicotinoyl hydrazone. We hypothesized that INH also binds and directly inhibits hALAS2. Using fluorescence-activated cell sorting and confocal fluorescence microscopy, we demonstrate that INH reduces protoporphyrin IX levels in HeLa cells expressing either wild-type hALAS2 or XLPP variants. In addition, PLP and pyridoxamine 5'-phosphate (PMP) reversed the cellular inhibition of hALAS2 activity by INH. Steady-state kinetic analyses with purified hALAS2 indicated that INH directly inhibits the enzyme, noncompetitively or uncompetitively, with an apparent K-i of 1.2 mu M. Circular dichroism spectroscopy revealed that INH triggered tertiary structural changes in hALAS2 that altered the microenvironment of the PLP cofactor and hampered the association of PLP with apo-hALAS2. Treatment of four XLPP patients with INH (5 mg.kg(-1).day(-1)) over a six-month period was well tolerated but without statistically significant modification of PPIX levels. These results, taken together, permit us to further an INH inhibition kinetic mechanism for ALAS, which suggests the possible use of INH-derived drugs in treating patients with XLPP and potentially other protoporphyrin-accumulating porphyrias. (C) 2016 Elsevier B.V. All rights reserved.

【 授权许可】

Free